| Rachael Marie Ferraro, DO | |
|
2003 Kootenai Health Way, Coeur D Alene, ID 83814 | |
| (208) 625-6900 | |
| (208) 625-6910 |
| Full Name | Rachael Marie Ferraro |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 19 Years |
| Location | 2003 Kootenai Health Way, Coeur D Alene, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902090350 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | O1194 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kootenai Health | Coeur d'alene, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kootenai Health Inc | 1355792276 | 330 |
News Archive
The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Los Angeles, CA and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.
Zcube Srl, a research venture of the Italian pharmaceutical company Zambon, and the California Institute of Technology (Caltech) have signed an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use. Mory Gharib, Hans W. Liepmann Professor of Aeronautics and professor of bioinspired engineering, is the principal investigator at Caltech.
Parkinson's experts across the world have been reporting a remarkable phenomenon - many patients treated with drugs to increase the activity of dopamine in the brain as a therapy for motor symptoms such as tremors and muscle rigidity are developing new creative talents, including painting, sculpting, writing, and more.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
› Verified 6 days ago
| Entity Name | Kootenai Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235288655 PECOS PAC ID: 4789641598 Enrollment ID: O20041214000230 |
News Archive
The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Los Angeles, CA and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.
Zcube Srl, a research venture of the Italian pharmaceutical company Zambon, and the California Institute of Technology (Caltech) have signed an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use. Mory Gharib, Hans W. Liepmann Professor of Aeronautics and professor of bioinspired engineering, is the principal investigator at Caltech.
Parkinson's experts across the world have been reporting a remarkable phenomenon - many patients treated with drugs to increase the activity of dopamine in the brain as a therapy for motor symptoms such as tremors and muscle rigidity are developing new creative talents, including painting, sculpting, writing, and more.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
› Verified 6 days ago
| Entity Name | Kootenai Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174661151 PECOS PAC ID: 1355792276 Enrollment ID: O20240111003252 |
News Archive
The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Los Angeles, CA and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.
Zcube Srl, a research venture of the Italian pharmaceutical company Zambon, and the California Institute of Technology (Caltech) have signed an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use. Mory Gharib, Hans W. Liepmann Professor of Aeronautics and professor of bioinspired engineering, is the principal investigator at Caltech.
Parkinson's experts across the world have been reporting a remarkable phenomenon - many patients treated with drugs to increase the activity of dopamine in the brain as a therapy for motor symptoms such as tremors and muscle rigidity are developing new creative talents, including painting, sculpting, writing, and more.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachael Marie Ferraro, DO 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-5085 | Rachael Marie Ferraro, DO 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Ph: (208) 625-6900 |
News Archive
The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Los Angeles, CA and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.
Zcube Srl, a research venture of the Italian pharmaceutical company Zambon, and the California Institute of Technology (Caltech) have signed an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use. Mory Gharib, Hans W. Liepmann Professor of Aeronautics and professor of bioinspired engineering, is the principal investigator at Caltech.
Parkinson's experts across the world have been reporting a remarkable phenomenon - many patients treated with drugs to increase the activity of dopamine in the brain as a therapy for motor symptoms such as tremors and muscle rigidity are developing new creative talents, including painting, sculpting, writing, and more.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
› Verified 6 days ago
Dr. Austin Voigt, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6910 | |
Dr. Timothy Clark Weill, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6910 | |
Farah Esther Vega, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-4000 | |
Dr. Scott D Loss, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6910 | |
Klinton Chad Kilgore, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6910 | |
Dr. Molly Kathleen Howlett, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6910 | |
Matthew Michael Kreps, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6910 |